AltruBio Taiwan Inc.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
AltruBio’s lead drug candidates are PSGL-1 agonist antibodies serving as immune checkpoint enhancers: ALTB-168, their first-generation molecule, has demonstrated safety and efficacy in Phase 1 and Phase 2 trials; and the next-generation ALTB-268, a tetrav
Founded Year
2020
Unified Business No.
82948968
Status
Active
Number of Employees
0
Total Paid-in
Capital
25,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AltruBio Inc. is a clinical-stage biotechnology company headquartered in San Francisco with an R&D center in Taipei. They specialize in developing first-in-class immune checkpoint enhancers (ICEs) for immunological and inflammatory diseases, backed by a world-class team with deep expertise in immunology and biologic drug development.
